Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide.
$11.76+0.68%
报价 2026-11-06
市值
$2.57B
EV
$3.32B
PE (TTM)
–
预期 PE (FY2027)
35.3x
52 周区间距高点 -15.9%
$5.41$13.98
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-05 | 1.0x | 0.36 → 0.44（1.2x） | 26.5 |
| FY+32029-05 | 1.0x | 0.36 → 0.60（1.7x） | 19.6 |
毛利率 47% · TTM 收入 $884M · 基数 EPS 0.36（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NEOGNeogen Corporation | $2.57B | +0.7% | +3.6% | 47.4% | – | 31.6x | 54.7x | |
| ZBIOZenas BioPharma, Inc. | $1.84B | +9.0% | -47.8% | 0% | – | – | – | |
| AZTAAzenta, Inc. | $1.72B | +4.8% | +4.0% | 44.9% | – | – | 173.6x | |
| KMTSKESTRA MEDICAL TECHNOLOGIES, LTD. | $1.72B | +0.9% | +51.5% | 56.5% | – | – | – | 高增长 |
| NTLAIntellia Therapeutics, Inc. | $1.59B | +2.3% | +5.3% | -46.5% | – | – | – | |
| NVCRNovoCure Limited | $1.55B | -2.0% | +12.9% | 77% | – | – | – | |
| CNMDCONMED Corporation | $1.53B | -2.5% | -0.4% | 56.4% | 21.3x | 10.9x | 11.6x | |
| OPKOPKO Health, Inc. | $1.29B | -1.1% | -4.7% | 48.9% | – | 26.2x | – | |
| TLRYTilray Brands, Inc. | $326.5M | +3.9% | – | 30.1% | – | – | – | |
| 同行中位数 | – | – | +4.0% | 46.9% | 21.3x | 18.6x | 92.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-08-31 Q1 2027 | 2026-05-31 Q4 2026 | 2026-02-28 Q3 2026 | 2025-11-30 Q2 2026 | 2025-08-31 Q1 2026 | 2025-05-31 Q4 2025 | 2025-02-28 Q3 2025 | 2024-11-30 Q2 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $222.8M | $225.3M | $211.2M | $224.7M | $209.2M | $225.5M | $221M | $231.3M |
| Gross Margin | 47.4% | 47.8% | 46.9% | 47.5% | 45.4% | 41.2% | 39.4% | 38.8% |
| Operating Margin | -0.8% | 1.4% | -1.6% | -2.4% | -7.7% | -5.9% | 5.4% | 7.4% |
| Net Income | $-11.9M | $-11.3M | $-17M | $-15.9M | $36.3M | $-612.2M | $-11M | $-456.3M |
| Diluted EPS | -0.05 | -0.05 | -0.08 | -0.07 | 0.17 | -2.82 | -0.05 | -2.1 |
| Operating Cash Flow | $12.9M | $30.2M | $22.7M | $19.4M | $10.9M | $16.5M | $19.4M | $40.3M |